Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.
A molecular test for Alzheimer's disease could lead to better treatment and therapies. We found 18 signaling proteins in blood plasma that can be used to classify blinded samples from Alzheimer's and control subjects with close to 90% accuracy and to identify patients who had mild cognitive impairment that progressed to Alzheimer's disease 2-6 years later. Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease.
Ray
Sandip
S
Satoris, Inc., 2686 Middlefield Road, Suite E, Redwood City, California 94063, USA.
Britschgi
Markus
M
Herbert
Charles
C
Takeda-Uchimura
Yoshiko
Y
Boxer
Adam
A
Blennow
Kaj
K
Friedman
Leah F
LF
Galasko
Douglas R
DR
Jutel
Marek
M
Karydas
Anna
A
Kaye
Jeffrey A
JA
Leszek
Jerzy
J
Miller
Bruce L
BL
Minthon
Lennart
L
Quinn
Joseph F
JF
Rabinovici
Gil D
GD
Robinson
William H
WH
Sabbagh
Marwan N
MN
So
Yuen T
YT
Sparks
D Larry
DL
Tabaton
Massimo
M
Tinklenberg
Jared
J
Yesavage
Jerome A
JA
Tibshirani
Robert
R
Wyss-Coray
Tony
T
D000544:Alzheimer Disease / Q000097:blood / Q000145:classification* / Q000175:diagnosis*; D015415:Biomarkers / Q000097:blood; D003072:Cognition Disorders / Q000097:blood / Q000145:classification / Q000175:diagnosis; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D010641:Phenotype; D011237:Predictive Value of Tests
D015415:Biomarkers; D036341:Intercellular Signaling Peptides and Proteins